Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

Guanfacine

Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures

DRUG

Methylphenidate (MPH)

Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.

Trial Locations (1)

90095

University of California Los Angeles, Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of California, Los Angeles

OTHER

NCT00429273 - Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter